Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia

BioEssays

Volumn 30, Issue 2, 2008, Pages 183-188

  Bebawy, Mary ^a   Chetty, Manoranjenni ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUNITROLOL; CHLORPROMAZINE; CLOZAPINE; DEXAMETHASONE; DIGOXIN; DOMPERIDONE; ETOPOSIDE; FLUPENTIXOL; FLUPHENAZINE; FLUVOXAMINE; GLYCOPROTEIN P; HALOPERIDOL; INDINAVIR; LOPERAMIDE; MOOD STABILIZER; NELFINAVIR; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; ONDANSETRON; PACLITAXEL; QUETIAPINE; QUINIDINE; RISPERIDONE; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

AGITATION; ANXIETY; BLOOD BRAIN BARRIER; CATATONIA; CELL MEMBRANE; DRUG EFFECT; DRUG POTENTIATION; HOSTILITY; HUMAN; MAJOR DEPRESSION; OBSESSIVE COMPULSIVE DISORDER; PREVENTION AND CONTROL; PROTEIN TRANSPORT; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD-BRAIN BARRIER; HUMANS; P-GLYCOPROTEIN; SCHIZOPHRENIA;

EID: 38849208598     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20706     Document Type: Review

References (60)

1. Conley RR, Buchanan RW. 1997. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 23:663-674.
2. Meltzer HY. 1992. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 18:515-542.
3. Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, et al. 1995. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv 46:801-806.
4. Essock SM, Hargreaves WA, Covell NH, Goethe J. 1996. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 32:683-697.
5. Arranz MJ, de Leon J. 2007. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 212:707-747.
6. Tishler DM, Weinberg KI, Hinton DR, Barbara N, Annett GM, et al. 1995. MDR1 gene expression in the brain of patients with medically intractable epilepsy. Epilepsia 36:1-6.
7. Sisodiya SM, Lin WR, Harding BM, Squier MV, Thom M. 2002. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125:22-31.
8. Loscher W, Potschka H. 2002. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 301: 7-14.
9. Boulton DW, DeVane CL, Liston HL, Markowitz JS. 2002. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 71:163-169.
10. Maines LW, Antonetti DA, Wolpert EB, Smith CD. 2005. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, Phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 49:610-617.
11. Qian W, Homma M, Itagaki F, Tachikawa H, Kawanishi Y, et al. 2006. MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biol Pharm Bull 29:2446-2450.
12. Lin Y-C, Ellingwood VL, Bishop JR, Jeffrey R, Miller DD. 2006. The relationship between p-glycoprotein polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit 28:668-672.
13. Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, et al. 2006. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog in Neuro-Psychopharmac and Biol Psychiatry 30:286-291.
14. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, et al. 2006. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 17.
15. Xing Q, Gao R, Li H, Feng G, Xu M, et al. 2006. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7:987-993.
16. Bebawy M, Morris MB, Roufogalis BD. 2001. Selective modulation of P-glycoprotein-mediated drug resistance. Br J Cancer 85:1998-2003.
17. American Psychiatric Association. 2004. Treatment recommendations for patients with schizophrenia. Amer J Psychiat 161:3-54.
18. Stahl SM, Grady MM. 2004. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11:313-327.
19. Anne K, Martin L. 2003. Polypharmacy in treatment with psychotropic drugs: the underestimated phenomenon. Current Opinion in Psychiatry 16:713-718.
20. Gisev N, Bell JS, McLachlan AJ, Chetty M, Chen T. 2006. Psychiatric Drug Use Among Patients of a Community Mental Health Service: Patterns and Implications. Disease Management and Health Outcomes 14:369-376.
21. Peacock L, Gerlach J. 1994. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 55:44-49.
22. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. 1999. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 37 Lilly Suppl: AS81-86.
23. Brosen K. 1996. Drug-Metabolizing Enzymes and Therapeutic Drug Monitoring in Psychiatry. Ther Dr Monit 18:393-396.
24. Fleming J, Chetty M. 2005. Psychotropic drug interactions with valproate. Clin Neuropharmacol 28:96-101.
25. Wang JS, DeVane CL, Gibson BB, Donovan JL, Markowitz JS, et al. 2006. Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology (Berl) 183:490-499.
26. Uhr M, Grauer MT, Holsboer F. 2003. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biological Psychiatry 54:840-846.
27. Nakagami T, Yasui-Furukori N, Saito M, Tateishi T, Kaneo S. 2005. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Therapeutics 78:43-51.
28. El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, et al. 2004. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56:967-975.
29. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
30. Higgins. 1995. The ABC of channel regulation. Cell 82:693-696.
31. Ford JM. 1996. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A:991-1001.
32. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, et al. 1999. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94:1086-1099.
33. Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, et al. 1993. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81:2394-2398.
34. Chan HS, Thorner PS, Haddad G, Ling V. 1990. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689-704.
35. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, et al. 1991. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608-1614.
36. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, et al. 1995. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380-1385.
37. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, et al. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695-698.
38. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. 1996. P-Glycoprotein in the Blood-Brain Barrier of Mice Influences the Brain Penetration and Pharmacological Activity of Many Drugs. J Clin Invest 97:2517-2524.
39. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. 2000. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237.
40. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, et al. 1997. Full Blockade of Intestinal P-glycoprotein and Extensive Inhibition of Blood-brain Barrier P-glycoprotein by Oral Treatment of Mice with P SC833. J Clin Invest 100:2430-2436.
41. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, et al. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir, an HIV protease inhibitor. Pharm Res 16:1206-1212.
42. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, et al. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 10:289-294.
43. Choo EF, Leake B, Wandel C, Immamura H, Wood AJ, et al. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Disp 28:655-660.
44. Hamabe W, Maeda T, Fukazawa Y, Kumamoto K, Shang LQ, et al. 2006. P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol, Biochem Behavior 85:629-636.
45. Potschka H, Fedrowitz M, Loscher W. 2002. P-glycoprotein mediated efflux of Phenobarbital, lamotrigine, and felbamate at the blood-brain barrier:evidence from microdialysis experiments in rats. Neurosci Lett 26:173-176.
46. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. 2006. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacol (Berl) 187: 415-423.
47. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, et al. 2006. Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data. J Pharmacol Exp Ther 317:704-710.
48. Sakata A, Tamai I, Kawazu K, Deguchi Y, Ohnishi T, et al. 1994. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem Pharmacol 48:1989-1992.
49. Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, et al. 1989. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 86:5128-5132.
50. Eytan GD, Borgnia MJ, Regev R, Assaraf YG. 1994. Transport of polypeptide ionophores into proteoliposomes reconstituted with rat liver P-glycoprotein. J Biol Chem 269:26058-26065.
51. Loe DW, Sharom FJ. 1994. Interaction of multidrug-resistant Chinese hamster ovary cells with the peptide ionophore gramicidin D. Biochim Biophys Acta 1190:72-84.
52. Sarkadi B, Muller M, Homolya L, Hollo Z, Seprodi J, et al. 1994. Interaction of bioactive hydrophobic peptides with the human multidrug transporter. Faseb J 8:766-770.
53. Sharma RC, Inoue S, Roitelman J, Schimke RT, Simoni RD. 1992. Peptide transport by the multidrug resistance pump. J Biol Chem 267:5731-5734.
54. Sharom FJ, Yu X, DiDiodato G, Chu JW. 1996. Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. Biochem J 320:421-428.
55. Beck WT, Cirtain MC, Look AT, Ashmun RA. 1986. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil. Cancer Res 46:778-784.
56. Volm M. 1998. Multidrug resistance and its reversal. Anticancer Res 18:2905-2917.
57. Syed SK, Christopherson RI, Roufogalis BD. 1998. Reversal of vinblastine transport by chlorpromazine in membrane vesicles from multidrug-resistant human CCRF-CEM leukaemia cells. Br J Cancer 78:321-327.
58. Tenforde TS, Yee JP, Mel HC. 1978. Electrophoretic detection of reversible chlorpromazine. HCl binding at the human erythrocyte surface. Biochim Biophys Acta 511:152-162.
59. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, et al. 2005. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503-514.
60. Hawkins BT, Egleton RD. 2007. Pathophysiology of the blood-brain barrier: animal models and methods. Curr Top Dev Biol 80:277-309.